New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Core Insights - The DecisionDx-SCC test significantly outperforms current staging systems in predicting local recurrence and metastasis for NCCN high-risk patients with cutaneous squamous cell carcinoma (SCC) [1][3][4] - The test provides individualized risk predictions that align with treatment decision-making for adjuvant radiation therapy (ART) and surveillance imaging [2][5] Study Findings - The first study demonstrates that DecisionDx-SCC predicts local recurrence in high-risk patients post-Mohs resection, adding a third validated use to the test [2][4] - The second study confirms that clinicians utilize test results to guide recommendations for ART and surveillance imaging based on individual patient risk [2][5] Clinical Implications - DecisionDx-SCC effectively stratifies risk among 414 NCCN high-risk SCC patients, showing three-year local recurrence-free survival rates of 95.3% for low risk (Class 1), 85.5% for higher risk (Class 2A), and 71.4% for highest risk (Class 2B) [4] - The test's predictive accuracy improves when combined with established clinicopathologic factors, enhancing risk stratification beyond traditional staging systems [4][5] Clinician Insights - A survey of 244 clinicians revealed that most recommend ART for patients with a ≥20% risk of local recurrence or metastasis and surveillance imaging for those with a ≥10% risk of metastasis [4][5] - Clinicians reported that Class 2B test results are among the most critical factors in management decisions for ART [5] Company Overview - Castle Biosciences, Inc. focuses on innovative diagnostic tests that guide patient care, with a portfolio that includes tests for skin cancers and other diseases with high clinical need [7][8] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [7]